The largest Insider Buys this week were for Delta Air Lines Inc. (DAL), DISH Network Corp. (DISH), IBERIABANK Corp. (IBKC), and PTC Therapeutics Inc. (PTCT).

Delta director bought 5,185 shares

Director Francis S. Blake bought 5,185 shares of Delta on Jan. 28 for an average price of $48.17 per share. The stock price has increased 3.63% since then.

Delta is a major American airline, operating over 5,400 flights daily. The company has a market capitalization of $34.23 billion; as of Feb. 1, it traded at $49.92.

On Jan. 15, the company reported fourth-quarter and full-year 2018 results. GAAP pretax income

Shares of PTC Therapeutics Inc. (PTCT) jumped on Monday on positive results from its open-label FIREFISH study evaluating risdiplam (RG7916) in babies with type 1 spinal muscular atrophy. Over 90% of the babies treated with risdiplam, a splicing modifier that targets the survival motor neuron 2 RNA, achieved more than a four-point increase in a test of motor skills called CHOP-INTEND. The median increase was 5.5 points.

"We are delighted that up to 6.5-fold increase of protein production has translated into clinical impact for these babies in the FIREFISH study," CEO Stuart W. Peltz, Ph.D., said. "The survival data and

Insider Peter Svennilson purchased 800,000 shares of Immune Design (IMDZ) on Sept. 19 at $6.25 per share, according to a Form 4Â filing for the Securities and Exchange Commission.

Since the trade, Immune Design’s market price has gained an estimated 21.28%.

Immune Design Corp. has a market cap of $152.94 million, an enterprise value of $52.11 million, a price-book (P/B) ratio of 1.76, a current ratio of 17.61 and a quick ratio of 17.49.

Immune Design Corp. is a clinical-stage immunotherapy company. The company is focused in oncology and engineers its technologies to activate

Michael Price (Trades, Portfolio), who manages private firm MFP Investors, is a value investor who looks for out-of-favor small cap companies with good value. His most significant second-quarter acquisition was a 1,625,000-share stake in Kearny Financial Corp. (KRNY), a holding company for Fairfield, N.J.-based Kearny Federal Savings Bank. He paid an average price of $10.42 per share in a deal that had a 2.39% impact on his portfolio.

Kearny Financial has a market cap of $1.05 billion and an enterprise value of $1.6 billion. It has a P/E of 90.6, a Price/Book of 2.1 and a Price/Sales

By Sarah Roden

The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology companies will be making presentations highlighting drug breakthroughs and updates. Analysts at Cowen & Co., led by Ritu Baral, highlighted what to watch for when several companies present at the annual meeting.

Biogen Inc (BIIB)

Cowen expects Biogen’s presentation at the AAN meeting to garner the highest level of investor focus. Baral expects Biogen to provide incremental data on aducanumab (BIIB037), a drug intended to treat Alzheimer’s disease. BIIB037 slows the growth